Medicines Reaches New 52-Week High (MDCO)

NEW YORK ( TheStreet) -- Medicines (Nasdaq: MDCO) hit a new 52-week high Wednesday as it is currently trading at $22.60, above its previous 52-week high of $22.48 with 356,275 shares traded as of 10:30 a.m. ET. Average volume has been 463,900 shares over the past 30 days.

Medicines has a market cap of $1.02 billion and is part of the health care sector and drugs industry. Shares are up 11.8% year to date as of the close of trading on Tuesday.

The Medicines Company, a global pharmaceutical company, provides various medicines to hospitals for advancing the treatment of critical care patients primarily in the United States and Europe. The company has a P/E ratio of 8.4, above the average drugs industry P/E ratio of six and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Medicines as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Medicines Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More

AveXis, Esperion and Amgen Among Biotech Movers